Ligand Pharmaceuticals
LGND
385 hedge funds and large institutions have $6.66B invested in Ligand Pharmaceuticals in 2018 Q3 according to their latest regulatory filings, with 65 funds opening new positions, 101 increasing their positions, 168 reducing their positions, and 22 closing their positions.
195% more first-time investments, than exits
New positions opened: 65 | Existing positions closed: 22
108% more call options, than puts
Call options by funds: $59.9M | Put options by funds: $28.8M
26% more capital invested
Capital invested by funds: $5.3B → $6.66B (+$1.36B)
11% more funds holding
Funds holding: 346 → 385 (+39)
9.88% less ownership
Funds ownership: 194.61% → 184.72% (-9.9%)
23% less funds holding in top 10
Funds holding in top 10: 13 → 10 (-3)
40% less repeat investments, than reductions
Existing positions increased: 101 | Existing positions reduced: 168
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$55.8M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$35.6M |
| 3 |
Millennium Management
New York
|
+$23.2M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$23.2M |
| 5 |
BlackRock
New York
|
+$19.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$87.1M |
| 2 |
GT
Glenmede Trust
Philadelphia,
Pennsylvania
|
-$43.4M |
| 3 |
Goldman Sachs
New York
|
-$34.9M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
-$29.2M |
| 5 |
William Blair Investment Management
Chicago,
Illinois
|
-$25.8M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
DTL
401
Dynamic Technology Lab
Singapore
| – | -$251K | -1,946 | Closed |
|
|
VHAM
402
Van Hulzen Asset Management
El Dorado Hills,
California
| – | -$218K | -1,683 | Closed |
|
|
FAM
403
Fred Alger Management
New York
| – | -$207K | -1,603 | Closed |
|
|
UFF
404
USA Financial Formulas
Ada,
Michigan
| – | -$91K | -882 | Closed |
|
405
Loomis, Sayles & Company
Boston,
Massachusetts
| – | -$11K | -83 | Closed |
|
|
TRCT
406
Tower Research Capital (TRC)
New York
| – | -$3K | -24 | Closed |
|
LGND Hedge Fund Activity: Q3 2018 in Review
385 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in Ligand Pharmaceuticals (LGND) for Q3 2018, worth a combined $6.66B — up 26% from $5.3B a quarter earlier.
Buyers outnumbered sellers: 65 funds opened new LGND positions and 22 closed out — a net gain of 43 holders — while 101 added to existing stakes and 168 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $55.8M. The largest seller was Deutsche Bank, cutting an estimated $87.1M.
- 385 institutional investors held Ligand Pharmaceuticals (LGND) as of Q3 2018, up from 346 in Q2 2018.
- Funds reported $6.66B of Ligand Pharmaceuticals stock for Q3 2018, up 26% quarter-over-quarter.
- 65 funds opened new Ligand Pharmaceuticals positions in Q3 2018 and 22 closed out, a net change of +43 holders.
- The largest Ligand Pharmaceuticals buyer in Q3 2018 was Renaissance Technologies, an estimated $55.8M added.
- The largest Ligand Pharmaceuticals seller in Q3 2018 was Deutsche Bank, an estimated $87.1M sold.
Based on aggregated 13F filings for Q3 2018.